BICX · XBRL financial data

BioCorRx financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BICX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	123	48	214	89	8	797
Cost of revenue	96	6	15	36	2	—
Cost of goods and services sold	—	—	19	—	—	—
Research and development	4,274	1,606	1,459	891	1,483	1,769
Selling, general and administrative	—	3,741	3,410	2,875	3,612	3,794
General and administrative	3,168	3,741	—	—	—	—
Total operating expenses	7,615	5,558	4,912	3,877	5,130	5,629
Operating income (loss)	(7,492)	(5,510)	(4,698)	(3,788)	(5,123)	(4,832)
Interest expense	511	19	151	194	777	224
Other income (expense)	—	299	321	—	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(3,507)	(5,211)	(4,377)	(3,770)	(5,212)	(3,440)
Earnings per share, diluted USD per share	—	—	—	—	(0.49)	(0.19)
Weighted average shares, diluted thousands of shares	1,141	1,055	1,448	2,697	3,378	18,486

Fiscal years (BICX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	592	86	69	65	88	139
Accounts receivable	—	—	35	1	0	253
Inventory	—	—	—	—	0	143
Total current assets	975	228	317	187	118	814
Property and equipment, net	129	103	77	51	19	4
Right-of-use asset	490	385	270	97	199	159
Goodwill	—	—	—	—	0	563
Total assets	1,827	820	767	389	386	2,147
Accounts payable	1,181	1,777	2,013	2,473	3,024	4,029
Accrued liabilities	—	—	—	—	—	496
Total current liabilities	3,052	4,386	5,364	6,431	8,208	8,306
Lease liability, non-current	435	316	181	11	159	116
Total liabilities	6,037	7,781	8,968	10,341	12,741	13,674
Accumulated deficit	(64,688)	(69,967)	(74,336)	(78,103)	(83,209)	(86,649)
Total stockholders' equity	(4,210)	(6,844)	(8,202)	(9,824)	(12,120)	(11,224)
Total liabilities and equity	1,827	820	767	389	386	2,147
Common shares outstanding (cover page) thousands of shares	6,598	6,946	7,737	8,815	16,099	26,403

Fiscal years (BICX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,507)	(5,211)	(4,377)	(3,770)	(5,212)	(3,440)
Stock-based compensation	355	210	355	277	1,219	593
Depreciation and amortization	—	64	27	—	33	44
Net cash from operating activities	(2,152)	(3,538)	(2,042)	(1,853)	(1,096)	(2,298)
Purchases of property and equipment	0	48	0	—	—	—
Net cash from investing activities	(9)	(50)	0	—	—	—
Proceeds from issuing common stock	0	2,250	1,250	—	700	—
Net cash from financing activities	107	3,081	2,025	1,850	1,119	2,350
Net change in cash	(2,054)	(506)	—	—	—	—

SIC 8093 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8093 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioCorRx	21	88	(440)*	29.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Pacific Health Care Organization	2,653	1,513	507*	12.8M	—	Q3 FY26 10-QSep 30, 2026
AnTix Holdings	14	not reported	not reported	70.7M	—	Q4 FY25 10-KJun 30, 2025
Marpai	138	4,166	(4,099)*	26.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
BioRestorative Therapies	3,113	23	(3,808)	25.5M	0.9 quarters	Q1 FY26 10-QMar 31, 2026
IMAC Holdings	45	21	(1,434)*	3.8M	0.0 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.